Patents by Inventor Sven Jacobson

Sven Jacobson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240299410
    Abstract: A method includes treatment of a familial ALS patient with oral fausdil at a dose of 180-240 mg/day. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.
    Type: Application
    Filed: May 15, 2024
    Publication date: September 12, 2024
    Inventors: Thomas MACALLISTER, Sven JACOBSON
  • Publication number: 20240299408
    Abstract: The present invention relates to the treatment patient with a 4-repeat (4R) tauopathy using a therapeutically effect amount of a rho kinase inhibitor. One preferred inhibitor is fasudil and preferred methods involve the daily oral administration of between 20 and 250 mg of fasudil. Preferred 4R tauopathies treatable according to the invention include progressive supranuclear palsy with Richardson syndrome (PSP-RS) and corticobasal syndrome with probable sporadic corticobasal degeneration.
    Type: Application
    Filed: January 8, 2021
    Publication date: September 12, 2024
    Inventors: Thomas MACALLISTER, Sven JACOBSON
  • Publication number: 20240261298
    Abstract: The invention relates to the treatment of patients with depression and or anxiety with high doses of rho kinase inhibitors. The maximum dose of a rho kinase inhibitor, based on fasudil hydrochloride as an exemplary agent, is more than 70 mg per day based on an immediate release formulation. Comparable dosing with other inhibitors is selected based on molar equivalents and/or rho kinase binding affinities. Treatable patients have one or more depressive disorders and/or one or more anxiety disorders.
    Type: Application
    Filed: May 16, 2022
    Publication date: August 8, 2024
    Inventors: Thomas MACALLISTER, Sven JACOBSON
  • Publication number: 20240252511
    Abstract: The invention relates to the treatment of patients with depression and or anxiety with low doses of rho kinase inhibitors. The maximum dose of a rho kinase inhibitor, based on fasudil hydrochloride as an exemplary agent, is less than 60 mg per day based on an immediate release formulation. Comparable dosing with other inhibitors is selected based on molar equivalents and/or rho kinase binding affinities. Treatable patients have one or more depressive disorders and/or one or more anxiety disorders.
    Type: Application
    Filed: May 16, 2022
    Publication date: August 1, 2024
    Inventors: Thomas MACALLISTER, Sven JACOBSON
  • Publication number: 20240100064
    Abstract: The invention relates to the treatment of neurodevelopmental disorders using an inhibitor of rho kinase. Preferred methods contemplate the treatment of infants and children. Certain embodiments involve treating a neurodevelopmental disorder is caused by defects of metabolism, including defects of amino acid transport or metabolism, acid-base balance, carbohydrate transport or metabolism, metal homeostasis, neurotransmitter metabolism, or fatty acid transport or metabolism. Methods address a variety of conditions caused by changes in the genetic material that affect the structure and/or expression of certain genes. Preferred methods treat Down syndrome, Fragile X syndrome, oligophrenin 1 deficiency, Rett syndrome, autistic disorder, Asperger's syndrome, pervasive developmental disorder not otherwise specified, and other autism spectrum disorders.
    Type: Application
    Filed: November 21, 2023
    Publication date: March 28, 2024
    Inventors: Thomas MACALLISTER, Sven JACOBSON
  • Patent number: 11865119
    Abstract: The invention is based on the discovery that rho kinase inhibitors, particularly fasudil can be used to treat agitation/anxiety in dementia patients, particularly Alzheimer's disease patients. Fasudil treatment of Alzheimer's patients resulted in improvements in agitation that are orders of magnitude to that observed with other potential therapeutic agents.
    Type: Grant
    Filed: March 2, 2023
    Date of Patent: January 9, 2024
    Assignee: WOOLSEY PHARMACEUTICALS, INC.
    Inventors: Thomas MacAllister, Sven Jacobson
  • Publication number: 20230414633
    Abstract: The present invention relates to the treatment of a sporadic ALS patient with oral fausdil at a dose of 180-240 mg/day. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.
    Type: Application
    Filed: September 7, 2023
    Publication date: December 28, 2023
    Inventors: Thomas MACALLISTER, Sven JACOBSON
  • Publication number: 20230405017
    Abstract: The present invention relates to methods of treating frontotemporal dementia. The methods are preferably accomplished by treatment with a rho kinase inhibitor, such as fasudil or hydroxyfasudil. In particular, the invention contemplates treatment of the behavioral variant frontotemporal dementia and usually treatment begins once symptoms become evident. Usually, patients treated according to the invention have no neuromuscular symptoms and generally have not been diagnosed with amyotrophic lateral sclerosis, corticobasal degeneration, Parkinson's Disease or progressive supranuclear palsy. A preferred method of the invention involves oral treatment with fasudil, administered in a total daily dose of between 70 mg and 140 mg.
    Type: Application
    Filed: January 8, 2021
    Publication date: December 21, 2023
    Inventors: Thomas MACALLISTER, Sven JACOBSON
  • Publication number: 20230321114
    Abstract: Methods of treating subjects with age-related cognitive decline with a rho kinase inhibitor are disclosed. In a preferred embodiment, the rho kinase inhibitor is fasudil and it is administered orally in a daily dose of between 70 and 250 mg per day. Subjects have a cognitive impairment on a global cognitive scale, like the MoCA or the MMSE and/or specific impairments related to different cognitive domains. A method of reducing the rate of age-related cognitive decline, comprising administering to a subject with evidence of age-related cognitive decline an effective amount of a rho kinase inhibitor. The inventive methods slow the rate of cognitive decline and/or improve cognition from baseline in treated individuals. The methods may result in enhancing processing speed, increasing attention, improving memory, improving language, improving visual construction skills and/or improving executive function in subjects experiencing age-related cognitive decline.
    Type: Application
    Filed: January 8, 2021
    Publication date: October 12, 2023
    Inventors: Thomas MACALLISTER, Sven JACOBSON
  • Patent number: 11779588
    Abstract: The present invention relates to the treatment of a sporadic ALS patient with oral fausdil at a dose of 180-240 mg/day. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: October 10, 2023
    Assignee: Woolsey Pharmaceuticals, Inc.
    Inventors: Thomas MacAllister, Sven Jacobson
  • Publication number: 20230310447
    Abstract: Methods of treating subjects with age-related cognitive decline with a rho kinase inhibitor are disclosed. In a preferred embodiment, the rho kinase inhibitor is fasudil and it is administered orally in a daily dose of between 30 and 60 mg per day. Subjects have a cognitive impairment on a global cognitive scale, like the MoCA or the MMSE and/or specific impairments related to different cognitive domains. A method of reducing the rate of age-related cognitive decline, comprising administering to a subject with evidence of age-related cognitive decline an effective amount of a rho kinase inhibitor. The inventive methods slow the rate of cognitive decline and/or improve cognition from baseline in treated individuals. The methods may result in enhancing processing speed, increasing attention, improving memory, improving language, improving visual construction skills and/or improving executive function in subjects experiencing age-related cognitive decline.
    Type: Application
    Filed: January 8, 2021
    Publication date: October 5, 2023
    Inventors: Thomas MACALLISTER, Sven JACOBSON
  • Patent number: 11771704
    Abstract: Disclosed are methods of treating patients with AD using a rho kinase inhibitor. A preferred rho kinase inhibitor used according to the invention is fasudil, which is typically administered orally in a total daily dose of 70-140 mg. A preferred dosing regimen involves administering the daily dose in three equal portions throughout the day. Preferred methods continue for more than one month and typically at least 2 or 3 months. Some preferred methods do not treat mild cognitive impairment and patients have and MMSE score of?23 and/or a CDR-SOB score of?4.5.
    Type: Grant
    Filed: February 28, 2023
    Date of Patent: October 3, 2023
    Assignee: Woolsey Pharmaceuticals, Inc.
    Inventors: Thomas MacAllister, Sven Jacobson
  • Publication number: 20230302011
    Abstract: Disclosed are methods of treating patients with AD using a rho kinase inhibitor. A preferred rho kinase inhibitor used according to the invention is fasudil, which is typically administered orally in a total daily dose of 70 - 140 mg. A preferred dosing regimen involves administering the daily dose in three equal portions throughout the day. Preferred methods continue for more than one month and typically at least 2 or 3 months. Some preferred methods do not treat mild cognitive impairment and patients have and MMSE score of ? 23 and/or a CDR-SOB score of ? 4.5.
    Type: Application
    Filed: February 28, 2023
    Publication date: September 28, 2023
    Inventors: Thomas MACALLISTER, Sven JACOBSON
  • Publication number: 20230285409
    Abstract: Disclosed are methods of treating patients with VaD using a rho kinase inhibitor. A preferred rho kinase inhibitor used according to the invention is fasudil, which is typically administered orally in a total daily dose of 70 - 180 mg. A preferred dosing regimen involves administering the daily dose in three equal portions throughout the day. Preferred methods continue for more than one month and typically at least 2 or 3 or even 6 months or more. Some preferred methods do not treat mild cognitive impairment and patients have and MMSE score of ? 23.
    Type: Application
    Filed: January 8, 2021
    Publication date: September 14, 2023
    Inventors: Thomas MACALLISTER, Sven JACOBSON
  • Publication number: 20230263806
    Abstract: The present invention relates to the treatment of conditions associated with a proteinopathy using a therapeutically effect amount of a rho kinase inhibitor. One preferred inhibitor is fasudil and preferred methods involve the daily oral administration of between 20 and 250 mg of fasudil. Proteinopathies preferably treated according to the invention involve aggregates of one or more of the following: amyloid beta, tau, Tar DNA Binding Protein 43 (TDP-43), Fused in sarcoma (FUS), ?-synuclein, Huntingtin, Superoxide dismutase 1 (SOD-1), Prion proteins (PrP), mutant forms of Transthyretin, Atrophin 1 (ATN1), the Androgen receptor (AR), Ataxin 1 (ATXN1), Ataxin 2 (ATXN2), Ataxin 3 (ATXN3), Calcium Voltage-Gated Channel Subunit Alpha1 (ACACNA1A), Ataxin 7 (ATXN7), Protein Phosphatase 2 Regulatory Subunit Bbeta (PPP2R2B), and Tata Box Binding Protein (TBP).
    Type: Application
    Filed: January 8, 2021
    Publication date: August 24, 2023
    Inventors: Thomas MACALLISTER, Sven JACOBSON
  • Publication number: 20230248739
    Abstract: The invention is based on the discovery that rho kinase inhibitors can be used to treat certain dementia-associated wandering. The inventive methods relate to the use of rho kinase inhibitors in the treatment of patients with cortical dementia-associated wandering. Preferred aspects of the invention contemplate treating wandering due to cortical vascular dementia and wandering due to dementia where the patient is a persistent wanderer and/or where the patient does not display a wayfinding defect.
    Type: Application
    Filed: April 14, 2023
    Publication date: August 10, 2023
    Inventors: Thomas MACALLISTER, Sven JACOBSON
  • Publication number: 20230226073
    Abstract: The invention is based on the discovery that rho kinase inhibitors can be used to treat proteinopathy associated wandering. A number of degenerative neurological diseases are thought to be caused, at least in part, by the formation of protein aggregates that cause neurotoxicity and progressive decline in function. The inventive methods related to the use of rho kinase inhibitors in the treatment of patients with proteinopathy-associated wandering. The patients may be suffering from Huntington's disease, a traumatic brain injury, autism spectrum disorder, Down syndrome or a proteinopathy-associated dementia, such as Alzheimer disease or frontotemporal dementia.
    Type: Application
    Filed: March 24, 2023
    Publication date: July 20, 2023
    Inventors: Thomas MACALLISTER, Sven JACOBSON
  • Publication number: 20230201219
    Abstract: The invention is based on the discovery that rho kinase inhibitors, particularly fasudil can be used to treat agitation/anxiety in dementia patients, particularly Alzheimer's disease patients. Fasudil treatment of Alzheimer's patients resulted in improvements in agitation that are orders of magnitude to that observed with other potential therapeutic agents.
    Type: Application
    Filed: March 2, 2023
    Publication date: June 29, 2023
    Inventors: Thomas MACALLISTER, Sven JACOBSON
  • Publication number: 20230190765
    Abstract: Disclosed are methods of treating patients with AD using a rho kinase inhibitor. A preferred rho kinase inhibitor used according to the invention is fasudil, which is typically administered orally in a total daily dose of 70-140 mg. A preferred dosing regimen involves administering the daily dose in three equal portions throughout the day. Preferred methods continue for more than one month and typically at least 2 or 3 months. Some preferred methods do not treat mild cognitive impairment and patients have and MMSE score of ?23 and/or a CDR-SOB score of ?4.5.
    Type: Application
    Filed: January 8, 2021
    Publication date: June 22, 2023
    Inventors: Thomas MACALLISTER, Sven JACOBSON
  • Patent number: 11666583
    Abstract: The invention is based on the discovery that rho kinase inhibitors can be used to treat certain dementia-associated wandering. The inventive methods relate to the use of rho kinase inhibitors in the treatment of patients with cortical dementia-associated wandering. Preferred aspects of the invention contemplate treating wandering due to cortical vascular dementia and wandering due to dementia where the patient is a persistent wanderer and/or where the patient does not display a wayfinding defect.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: June 6, 2023
    Assignee: Woolsey Pharmaceuticals, Inc.
    Inventors: Thomas Macallister, Sven Jacobson